Nutriband Revolutionizes Opioid Abuse Prevention with Commercial Scale Manufacturing of Aversa(TM) Fentanyl Abuse Deterrent Formulation

Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) and Kindeva Drug Delivery have made a breakthrough in the fight against substance abuse: the selection of the AVERSA™ formulation to take forward into commercial scale manufacturing process development.

This patented lead product, AVERSA™ Fentanyl, is an abuse-deterrent fentanyl transdermal system that utilises Nutriband’s proprietary transdermal technology. It can be manufactured using standard commercial transdermal manufacturing processes, and is now available in a variety of transdermal patch products. This is a major advancement in the fight against substance abuse.

Nutriband and Kindeva have teamed up to revolutionize opioid delivery with the introduction of AVERSA™ Fentanyl. This groundbreaking abuse-deterrent transdermal technology is already estimated to be worth between $80 million and $200 million annually in the US markets.

AVERSA™ Fentanyl is the first of its kind to combine Nutriband’s proprietary abuse-deterrent transdermal technology with Kindeva’s FDA-approved transdermal fentanyl patch system, allowing for a safe and effective delivery of opioids.

At Nutriband, we are thrilled to be collaborating with Kindeva Drug Delivery to bring Aversa Fentanyl to the market – the world’s first abuse deterrent pain patch. We are making great strides towards making this revolutionary product available to those in need of pain relief.

Kindeva and Nutriband are proud to join forces and announce their strategic partnership in order to create combination products for patients all over the world. With Kindeva’s comprehensive knowledge in drug-device methods such as transdermal administration, and Nutriband’s expertise, the two companies promise to develop innovative treatments and improve the lives of patients everywhere.

According to Kindeva CEO Milton Boyer, “Partnering together to formulate and develop combination products for patients worldwide is core to our business. We are delighted to have Nutriband’s support in this endeavor.”

Nutriband’s AVERSA™ abuse-deterrent technology offers a unique solution to combat the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. By incorporating aversive agents into transdermal patches, this revolutionary technology has the potential to not only improve the safety profile of drugs such as fentanyl, but also make sure that these treatments remain accessible to those who truly need them. This technology is backed by a strong patent portfolio, with patents awarded in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.

About Nutriband Inc.

We are developing a revolutionary portfolio of transdermal pharmaceutical products, with our leading product being an abuse deterrent fentanyl patch powered by our AVERSA™ abuse deterrence technology.

Our groundbreaking technology can be integrated into any transdermal patch to protect against abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. We are paving the way for a safer world with our powerful solutions!

About Kindeva Drug Delivery

Kindeva is an international leader in contract development and manufacturing of drug-device combination products. With a wide range of advanced formats, including autoinjectors, inhalers, transdermal patches and microneedles, Kindeva provides a comprehensive service offering from early-stage feasibility to commercial scale drug product fill-finish, container closure system manufacturing and drug-device product assembly. Boasting nine manufacturing and research and development facilities in the U.S. and U.K, Kindeva is a trusted partner to a global customer base.

Leave a Comment